Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
نویسنده
چکیده
Overview. Clinical types of MS. MS is a chronic recurrent inflammatory disorder of the CNS. The disease results in injury to the myelin sheaths, the oligodendrocytes, and, to a lesser extent, the axons and nerve cells themselves.1-5 The symptoms of MS vary, depending in part on the location of plaques within the CNS. Common symptoms include sensory disturbances in the limbs, optic nerve dysfunction, pyramidal tract dysfunction, bladder or bowel dysfunction, sexual dysfunction, ataxia, and diplopia.5 Four different clinical courses of MS have been defined.6 The first, relapsing–remitting MS (RRMS), is characterized by self-limited attacks of neurologic dysfunction. These attacks develop acutely, evolving over days to weeks. Over the next several weeks to months, most patients experience a recovery of function that is often (but not always) complete. Between attacks the patient is neurologically and symptomatically stable. The second clinical course, secondary progressive MS (SPMS), begins as RRMS, but at some point the attack rate is reduced and the course becomes characterized by a steady deterioration in function unrelated to acute attacks. The third clinical type, primary progressive MS (PPMS), is characterized by a steady decline in function from the beginning without acute attacks. The fourth type, progressive–relapsing MS (PRMS), also begins with a progressive course although these patients also experience occasional attacks.
منابع مشابه
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
متن کامل
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
2010;74;691 Neurology Hans D. Katzberg, Ahmir H. Khan and Yuen T. So of Neurology Technology Assessment Subcommittee of the American Academy evidence-based review) : Report of the Therapeutics and Assessment: Symptomatic treatment for muscle cramps (an January 10, 2013 This information is current as of http://www.neurology.org/content/74/8/691.full.html located on the World Wide Web at: The onl...
متن کاملEvidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
OBJECTIVE The chemotherapeutic agent mitoxantrone was approved for use in multiple sclerosis (MS) in 2000. After a review of all the available evidence, the original report of the Therapeutics and Technology Assessment Subcommittee in 2003 concluded that mitoxantrone probably reduced clinical attack rates, MRI activity, and disease progression. Subsequent reports of decreased systolic function,...
متن کاملNeuropsychological testing of adults: further considerations for neurologists.
The recent report on neuropsychological testing of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (AAN) has implications for neuropsychologists as well as neurologists. The subcommittee's report omits mention of standardized neuropsychological test batteries used by a majority of practicing neuropsychologists, and of the demonstrated validity of suc...
متن کاملSubcommittee of the American Academy of Neurology Evidence-based Review): Report of the Therapeutics and Technology Assessment Assessment: Botulinum Neurotoxin for the Treatment of Movement Disorders (an Assessment: Botulinum Neurotoxin for the Treatment of Movement Disorders (an Evidence-based Review)
2008;70;1699-1706 Neurology Jankovic, B. Karp, C. L. Ludlow, J. M. Miyasaki, M. Naumann and Y. So D. M. Simpson, A. Blitzer, A. Brashear, C. Comella, R. Dubinsky, M. Hallett, J. Subcommittee of the American Academy of Neurology evidence-based review): Report of the Therapeutics and Technology Assessment Assessment: Botulinum neurotoxin for the treatment of movement disorders (an This informatio...
متن کامل